Engflag

Galantamina Teva

Quick links to important sections

Galantamina Teva

Selected form

Galantamina Teva_EN

Method of action: Anticholinesterase, Lipid Modifying Agents, M-N-Cholinomimetic, Psychoanaleptics

Treatment option: Dementia

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Galantamina Teva

Quick Facts

Property Description
Active Ingredient Galantamine Hydrobromide (INN: Galantamine)
Form Oral tablets, oral solution, and extended-release capsules
Pharmacological Class Acetylcholinesterase Inhibitor (AChEI)
Common Use Symptomatic support for memory and thinking
Origin Tertiary alkaloid, derived from plants; commercially semi-synthetic

Galantamina Teva: Identity, Type, and Composition

Galantamina Teva is a prescription-only medicine that contains the active substance Galantamine Hydrobromide. It is a single-component product classified as an Acetylcholinesterase Inhibitor (AChEI), a class of drugs that acts on the central nervous system. Galantamine is chemically identified as a tertiary alkaloid, whose structure is derived from compounds naturally found in plants of the Amaryllidaceae family. The pharmaceutical-grade ingredient, however, is often produced via semi-synthesis to ensure consistent quality and scale.

The medicine is supplied for oral administration and is available in various forms, including immediate-release tablets, an oral solution, and extended-release capsules. The inclusion of a prolonged-release capsule formulation, manufactured by Teva Pharmaceutical Industries, is a key differentiating factor that allows for gradual drug release over time, which supports sustained therapeutic activity.

Pharmacological Classification and General Purpose

The fundamental purpose of Galantamine Hydrobromide is to enhance cholinergic function in the brain, an action that is clinically recognized for supporting cognitive abilities. Its core mechanism involves the competitive and reversible inhibition of the acetylcholinesterase enzyme, which preserves the vital neurotransmitter acetylcholine. The conclusion drawn from this fact is that the medicine essentially helps to boost the signaling pathways utilized for cognitive processes.

Galantamine is further distinguished by its dual mode of action: it also functions as an allosteric modulator of nicotinic acetylcholine receptors (nAChR). This combined effect—both protecting and potentiating the neurotransmitter—is applied to provide symptomatic treatment aimed at supporting and maintaining key mental abilities, such as memory and thinking.

Regulatory References

  1. NIH/NCI Drug Dictionary: Galantamine Hydrobromide

What side effects are possible with Galantamina Teva?

Possible Side Effects and Safety Information

Galantamina Teva, which contains the active substance Galantamine Hydrobromide, has an official safety profile primarily characterized by adverse reactions related to its mechanism of action, with high frequencies observed early in treatment. The most commonly documented adverse effects are classified as Very Common or Common in regulatory labeling, predominantly affecting the Gastrointestinal Disorders and Nervous System Disorders.

Official Side Effect Classifications

Frequency Category Key Adverse Reactions (Examples)
Very Common Nausea, Vomiting
Common Dizziness, Headache, Bradycardia (slow heart rate), Diarrhoea, Decreased appetite, Fall, Syncope
Uncommon / Rare Seizures, Atrioventricular (AV) block, Hypersensitivity, Hepatitis, Severe skin reactions (e.g., Stevens-Johnson Syndrome)

Certain effects, such as nausea and vomiting, are noted as being more frequent during the initial dose titration period. Dizziness and somnolence are often particularly apparent during the first few weeks of treatment.

General and Population-Specific Safety Restrictions

Official labeling defines clear safety constraints for use. Galantamina Teva is contraindicated in patients with severe hepatic impairment (Child-Pugh score >9) or severe renal impairment (creatinine clearance <9 mL/min). Furthermore, caution is required in patients with a history of peptic ulcer disease, certain cardiac conduction abnormalities, and urinary outflow obstruction, reflecting documented safety risks associated with the medicine.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for Galantamina Teva (Galantamine Hydrobromide) is characterized by an exaggeration of its intended effects, leading to a state known as cholinergic crisis. The regulatory documentation mandates that immediate medical attention be sought upon the suspicion of an overdose, requiring contact with a Poison Control Center or emergency services.

Documented Clinical Manifestations

Official labeling describes overdose symptoms as severe gastrointestinal distress, including nausea, vomiting, and gastro-intestinal cramping, alongside systemic effects such as salivation, sweating, and increasing muscle weakness (fasciculations). Severe outcomes include bradycardia (slow heart rate), hypotension, and the potential for respiratory depression and cardiac collapse; serious rhythm disorders like Torsades de pointes have been reported.

Official Emergency Management

Close supervision and hospital treatment are required for severe events. The regulatory information specifies that Intravenous atropine sulfate may be used by medical personnel as a documented antidote and supportive measure. General supportive measures must be utilized in the management of an overdose. Patients with moderate to severe liver or kidney impairment have an officially noted higher risk profile due to reduced drug clearance, increasing the potential for severe manifestations.

Therapeutic Uses of Galantamina Teva

What Galantamina Teva Treats: Main Uses and Benefits

Galantamina Teva is generally indicated for the symptomatic treatment of mild to moderate dementia of the Alzheimer's type. The medicine is applied across domains where additional symptomatic support is needed, primarily for managing symptoms that interfere with daily functioning, such as impaired memory and difficulty reasoning.

The primary conditions relevant to its use include Alzheimer’s disease, vascular dementia, and mixed dementias. The treatment is applied to support these key cognitive abilities, and may assist with managing symptoms related to the disease's progressive nature. This symptomatic support contributes to the patient's capacity to perform routine daily activities, which assists with maintaining functional stability and helps ease the overall symptom load over time. The treatment is commonly used across conditions presenting with chronic manifestations of cognitive and behavioral change, supporting patients during difficult episodes by easing distress.

Quick Fact: Relief for Cognitive Decline
Symptomatic Focus Symptomatic management of memory and thinking abilities.
Supportive Role Assists with maintaining functional stability during routine daily activities.
Clinical Focus Mild to moderate dementia of the Alzheimer's type.

Regulatory References

  1. FDA Labeling via NIH DailyMed

Eligibility and Restrictions for Use

Galantamina Teva's eligibility is strictly defined by regulatory documents, limiting use to adults diagnosed with mild to moderate dementia of the Alzheimer's type.

Who Must Not Use Galantamina Teva (Contraindications)

The medicine is contraindicated and must not be used by patients with:

  • Known hypersensitivity to galantamine hydrobromide or any of the formulation's excipients [Source 1.3].
  • Severe hepatic impairment (Child-Pugh score > 9) or severe renal impairment (creatinine clearance < 9 mL/min) [Source 2.3, 2.5].

Restricted and Conditional Use

Use is restricted or conditional in other populations due to altered drug clearance or specific conditions:

  • Moderate hepatic or renal impairment (Creatinine clearance 9-59 mL/min or Child-Pugh score 7-9): The use is permitted, but the maximum daily dose is officially limited [Source 1.4, 2.3].
  • The medicine is not recommended for use in children under 18 as safety and efficacy have not been established [Source 1.7].
  • The medicine is not indicated for patients with Mild Cognitive Impairment (MCI) [Source 2.1].
  • Caution is required for patients with certain pre-existing conditions, including severe asthma, specific heart rhythm problems, or a history of ulcers [Source 1.4, 1.7].
  • Use during pregnancy or lactation is generally not recommended due to a lack of adequate human safety data [Source 3.1].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Galantamina Teva's interaction profile is primarily governed by its metabolic clearance pathways and its core functional activity as a cholinomimetic.

Drug–Drug Interaction Constraints

Co-administration with other cholinesterase inhibitors or cholinomimetics (such as donepezil or rivastigmine) is a strictly documented restriction due to the potential for severe additive pharmacodynamic effects.

Interacting Substance Category Regulatory Outcome Official Mechanism Basis
CYP2D6 & CYP3A4 Inhibitors Increased Galantamine plasma exposure (AUC) Pharmacokinetic Inhibition
Vagotonic Agents (e.g., Digoxin, Beta-blockers) Increased risk of bradycardia/AV block Additive Pharmacodynamic Effect
NSAIDs Increased risk of gastrointestinal bleeding Risk Factor Co-administration
Succinylcholine Exaggeration of neuromuscular blockade Pharmacodynamic Effect

Substances that inhibit the CYP2D6 enzyme (like paroxetine) or the CYP3A4 enzyme (like ketoconazole) are explicitly documented to reduce galantamine clearance, resulting in a clinically significant increase in systemic exposure. Additionally, the medicine may antagonise the therapeutic effect of anticholinergic medications.

Administration-Related Interactions

Galantamine is directed to be taken preferably with food to mitigate documented gastrointestinal issues. Regulatory cautions note that consumption of alcohol may increase the risk of certain central nervous system effects, such as dizziness. The relevance of pharmacokinetic interactions is officially heightened in patient populations with impaired renal or hepatic function.

Mechanism of Action

Dual Mode of Action: Cholinesterase Inhibition and Receptor Potentiation

Galantamine utilizes a dual mode of action within the central nervous system, first by reversibly inhibiting the enzyme Acetylcholinesterase ( AChE) to protect the neurotransmitter acetylcholine ( ACh) from being rapidly hydrolyzed. Simultaneously, it acts as a Positive Allosteric Modulator (PAM) on neuronal nicotinic acetylcholine receptors ( nAChR). This two-part action fundamentally strengthens the cholinergic signaling pathway, influencing neurocircuitry involved in signal transduction and information exchange.

Cascade Effects on Secondary Neurotransmitter Systems

Beyond protecting ACh, the allosteric modulation of presynaptic nAChR triggers a crucial mechanistic cascade. This enhances the release of other critical signaling molecules in the brain, including dopamine and norepinephrine, which are chemical signals released as part of synaptic regulatory mechanisms. This cascade influences systems beyond the primary cholinergic pathway, altering neural signaling dynamics and the pattern of signal transduction.

Constraints of the Mechanistic Scope

Galantamine's function is limited to molecular actions that adjust the efficiency of existing biological pathways. Its effect is entirely dependent on the continued presence of functionally viable cholinergic neurons that are still able to synthesize and release ACh. The mechanism is structurally constrained as it does not influence the cellular processes responsible for neuronal attrition.

Dosage and Administration Information

How to Use Galantamina Teva: Official Administration Guidelines

Galantamina Teva (Galantamine Hydrobromide) is administered exclusively via the oral route and is available as immediate-release (IR) tablets, oral solution, and extended-release (ER) capsules.

Treatment must follow a titration schedule, starting at a low dose and gradually increasing to minimize potential adverse effects. The maximum recommended daily dose is 24 mg.

Standard Dosing and Schedule

Formulation Starting Dose Frequency Maximum Dose Titration Logic
IR Tablets/Solution 4 mg Twice daily (BID) 24 mg/day Dose increase occurs after a minimum of four weeks at the preceding dose.
ER Capsules 8 mg Once daily (QAM) 24 mg/day Dose increase occurs after a minimum of four weeks at the preceding dose.

Key Administration Instructions

  • Intake Conditions: Galantamina Teva should be taken with meals (morning and evening for IR; morning for ER) and with adequate fluid intake.
  • Handling: Extended-release capsules must be swallowed whole and should not be crushed, chewed, or divided.
  • Treatment Interruption: If therapy is interrupted for more than three days, treatment must be restarted at the lowest dosage (8 mg/day) and re-titrated to the required level.

Population-Specific Use

Dosage adjustments are mandated for specific patient groups:

  • Moderate Renal/Hepatic Impairment: The maximum daily dose should generally not exceed 16 mg.
  • Severe Renal/Hepatic Impairment: Use is generally not recommended.
  • Pediatrics: The medicine is not recommended for patients under 18 years of age.

Recent Clinical Evidence

Recent Clinical Evidence Summary

Galantamina Teva is indicated for the symptomatic treatment of mild to moderately severe dementia of the Alzheimer's type. Clinical research has focused on the drug's effect on cognitive function, global performance, and activities of daily living over 6-month and longer-term trials.

Cognitive and Functional Outcomes

Randomized, placebo-controlled trials have consistently evaluated patient outcomes using standardized measures, primarily the Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS-cog) and the Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus).

Outcome Measure Research Finding (vs. Placebo)
Cognitive Function (ADAS-cog) Evidence suggests a statistically significant, although modest, difference favoring galantamine in slowing cognitive decline at 6 months.
Global Function (CIBIC-Plus) Research indicates a favorable effect on the clinical impression of overall function.
Activities of Daily Living (DAD) Study findings show an apparent difference in the rate of decline of functional abilities.

Safety and Tolerability Profile

The adverse event profile of galantamine is a major focus of clinical studies. Gastrointestinal events were frequently reported, with nausea, vomiting, and diarrhea being the most common side effects observed in the treatment groups compared to placebo.

Research has also documented cardiovascular events due to the drug's effect on the sinoatrial and atrioventricular nodes, which can lead to bradycardia (slow heart rate) and syncope (fainting). Patients in clinical trials for mild cognitive impairment showed a higher mortality rate compared to placebo, a finding whose relevance to Alzheimer's treatment remains unclear.

How should Galantamina Teva be stored and disposed of?

Storage and Environmental Controls

The storage requirements for Galantamina Teva are based on the specific formulation. Extended-release capsules must be stored between 15 C and 30 C (Controlled Room Temperature), while the tablets and oral solution should be stored at room temperature.

The medication must be kept in the container it came in, which should be tightly closed. It must be protected from excess heat and moisture and must not be frozen.

Stability and Child Safety

The Galantamina Teva oral solution is required to be stored in the original bottle to protect from light. Furthermore, it must be discarded 90 days after first opening.

All forms of the medication must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Galantamina Teva must be disposed of in accordance with local regulatory requirements. The product should not be flushed down the toilet or poured down a drain unless specific instructions on the label advise otherwise.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagPortugal

Equivalent of Galantamina Teva found in:

A-Z Index: